Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash from Operations (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Cash from Operations for 10 consecutive years, with 5516000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 133.94% year-over-year to 5516000.0, compared with a TTM value of 1598000.0 through Dec 2025, up 97.71%, and an annual FY2025 reading of 1598000.0, up 97.71% over the prior year.
  • Cash from Operations was 5516000.0 for Q4 2025 at Zevra Therapeutics, up from 4709000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 16603000.0 in Q2 2021 and bottomed at 19109000.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 5653800.0, with a median of 4283000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations skyrocketed 657.09% in 2021, then plummeted 426.18% in 2022.
  • Year by year, Cash from Operations stood at 848000.0 in 2021, then tumbled by 426.18% to 4462000.0 in 2022, then plummeted by 262.12% to 16158000.0 in 2023, then fell by 0.57% to 16250000.0 in 2024, then surged by 133.94% to 5516000.0 in 2025.
  • Business Quant data shows Cash from Operations for ZVRA at 5516000.0 in Q4 2025, 4709000.0 in Q3 2025, and 3601000.0 in Q2 2025.